Aktienanalyse zu Mirum Pharmaceuticals Inc (MIRM)MIRMMirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Mirum Pharmaceuticals Inc is a good buy right now due to its current price of $80.39, which is significantly lower than the analyst price targets ranging from $152 to $200. The company has shown a gross margin of 82.78% in Q2 2026, indicating strong profitability potential. However, the main risk is the negative earnings per share (EPS) of -1.06 in Q2 2026, which reflects ongoing losses that could impact investor sentiment.